Board of Directors

Christopher S. Meldrum, Chairman

Mr. Meldrum serves as Chairman of the Board of Directors for Kylin. Mr. Meldrum is Managing Director at Golden Pine Ventures, and has worked extensively with development-stage biotechnology and medical device companies, founding and helping to secure financing for seven biomedical start-up ventures. Mr. Meldrum also currently serves as President and a Director of Pique Therapeutics, a biotechnology company focused in oncology, with a lead product in Phase II clinical trials.

Before joining Golden Pine Ventures in 2004, Mr. Meldrum was Director, Corporate Alliances, at Paradigm Genetics, a publicly-traded biotechnology company, where he led business development efforts for both the healthcare and agriculture businesses. He held business development positions of increasing responsibility since joining the company in the summer of 2000. During his time at Paradigm, he negotiated to completion seven revenue-generating collaborations with deal values totaling over $30 million.

Before his time at Paradigm, Mr. Meldrum worked as Licensing Associate for Purdue University, where he managed the out-licensing of Purdue’s biotechnology and life sciences portfolio. Prior to his time at Purdue, he worked for two years in the University of Minnesota’s technology transfer office. Over the course of his career, he has successfully led negotiations for more than 70 fully-executed deals.

Mr. Meldrum received his MBA from the Carlson School of Management at the University of Minnesota and his B.A. in Chemistry from the University of Utah.

Homer L. Pearce, Ph.D., Director and Scientific Advisor

Dr. Pearce recently retired from Lilly Research Laboratories, where he served as a member of the executive leadership in discovery research. Of particular note was his tenure as vice president of cancer research and clinical investigation. At the time of his retirement, Dr. Pearce held the title of distinguished research fellow.

While he was VP of cancer research at Eli Lilly, Dr. Pearce led Lilly’s collaboration with Isis Pharmaceuticals. The relationship with Isis was to discover antisense drugs to inhibit specific gene targets associated with cancer, especially antisense compounds directed at cellular regulators of apoptosis. The Isis-Lilly relationship also looked to discover new antisense drugs in the fields of inflammatory and metabolic diseases.

In his more than 27 years devoted to cancer drug discovery at Lilly, Dr. Pearce was involved in the development of more than 25 investigational drugs which entered clinical trials for cancer, of which three have resulted in regulatory approvals and others are still in development. These drugs, which include Gemzar® and Alimta®, achieved 2005 combined worldwide sales of nearly 2 billion dollars. Another drug which advanced during this period, the molecular targeted therapeutic, enzastaurin, is now in Phase III clinical trials.

Dr. Pearce’s graduate work at Harvard – the total synthesis of picrotoxinin, which was considered to be an impossible problem by none other than the scientist who originally decoded the structure of the picrotoxinin family – remains one of the landmark achievements in the area of natural products total synthesis. What makes it even more remarkable is that it was a feat he accomplished single-handedly.

Dr. Pearce currently serves as a Board Member, Scientific Advisor, or Business Director to a number of leading research institutions, foundations and biotechnology companies. The recipient of numerous awards throughout his career, Dr. Pearce was most recently named “A Hero of Chemistry” by the American Chemical Society, for his discovery and development of Alimta®, the first drug ever approved for the treatment of malignant pleural mesothelioma.

Dr. Pearce received his Ph.D. in chemistry from Harvard University and his undergraduate degree from Texas A&M University

J. Eric Davis, President, CEO, and Director

J. Eric Davis serves as Kylin’s President, Chief Executive Officer, and a Director of the Company. Mr. Davis, one of the Founders of In-vivo Ventures, LLC, is also one of the original founders of the Company. In 2005, Mr. Davis co-founded Quadraspec, Inc., a venture-backed medical diagnostics company with a proprietary detection platform for blood and cellular-based biomarkers. Mr. Davis also founded Arxan Technologies Inc., a venture-backed software security company based upon technology originally licensed from CERIAS at Purdue University. Arxan has since grown to become a leading provider of system security to the United States Department of Defense and commercial independent software vendors with high value intellectual property.

Prior to starting Arxan, Mr. Davis co-founded Copient Technologies, LLC, and served as its President and CFO. While at Copient, Mr. Davis participated in the development of its financing. He also managed all business operations of the company including personnel, legal compliance, M&A activity, and financial planning. Copient was acquired by NCR Corporation in 2003. Mr. Davis also served Purdue University through its Office of Technology Commercialization for several years.

Mr. Davis received his B.S. from the University of Dayton and his J.D. from Indiana University.